Avicanna Inc. Reports Strong Q3 2025 Results
TORONTO — Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) has announced its financial results for the third quarter of 2025. The biopharmaceutical company is dedicated to the development and commercialization of plant-derived cannabinoid-based products.
CEO's Insights on Q3 Performance
CEO Aras Azadian shared, "Q3 reflects our ongoing commitment to building a sustainable biopharmaceutical business. We are thrilled by our medical affairs initiatives that have facilitated increased engagement within Canada’s medical community, leading to sustained revenue growth. Our scientific leadership continues to yield tangible results through new intellectual property and global partnerships, ensuring our focus on disciplined execution and long-term shareholder value remains strong despite short-term challenges to our margins."
Financial Highlights for Q3 2025
The company reported impressive financial results for the quarter ending September 30, 2025. Revenue reached $6.40 million for the three-month period and $18.88 million for the nine-month period. The Canadian revenue saw a 4% increase, emphasizing the effectiveness of enhanced medical affairs initiatives. International revenues also experienced a increase of approximately 6% compared to the previous quarter.
Revenue Breakdown
The gross profit for the quarter amounted to $3.15 million, with gross margins reaching 49%. While this represented a slight decline from the previous year, improvements were noted in the nine-month margins, attributed to shifts in sales from direct product sales to licensing and service revenue. The adjusted EBITDA reflected a loss of $0.79 million for Q3, indicating a small improvement compared to a year ago.
Q3 2025 Notable Corporate Achievements
Several significant achievements marked Avicanna's activities in Q3 2025. The company noted an impressive increase in Canadian sales, achieving a record of 62,987 units sold—a 39% increase from Q3 2024. Furthermore, Avicanna's commercial offerings expanded, boasting 52 SKUs and 174 listings across medical and adult-use markets.
New Patent Issued
Avicanna announced that the United States Patent and Trademark Office issued a patent for innovative topical cannabinoid compositions aimed at promoting clear skin. This development aligns with the company's ongoing commitment to pioneering cannabinoid-based therapies.
International Expansion
Furthermore, Avicanna successfully completed its first export of organic certified CBD-dominant cannabis flower into Europe. This marked a significant milestone as the company continues to enhance its international footprint and meet the growing demands for medical cannabis in various regions.
Innovative Product Launches
Avicanna's dedication to health and wellness is highlighted by the launch of the re+PLAY CBD wellness brand topicals in collaboration with Harrington Wellness. This initiative features products developed from Avicanna's proprietary formulations and illustrates its commitment to providing effective wellness solutions.
About Avicanna Inc.
Avicanna is a commercial-stage international biopharmaceutical company that emphasizes the advancement of cannabinoid-based medications and related products for global medical markets. Its established scientific framework enables the company to introduce over thirty proprietary, evidence-based products across multiple commercial stages, along with ongoing research endeavors.
Product Offerings
Among Avicanna's diverse product lines is the RHO Phyto™ medical cannabis formulary, which offers a range of cannabinoid products tailored to various patient needs. The company also operates MyMedi.ca, a platform designed to enhance the patient experience in the medical cannabis sector through education and support.
Market Presence and Future Outlook
Avicanna's focus on developing cannabinoid-based pharmaceutical candidates, including treatments for dermatology and chronic pain, underscores its commitment to addressing unmet needs in the healthcare landscape. With a robust supply chain including its subsidiary, Santa Marta Golden Hemp SAS, the company is well-positioned for growth.
Frequently Asked Questions
What are Avicanna's main business segments?
Avicanna operates in multiple segments, including research, development, and commercialization of cannabinoid products along with medical cannabis education platforms.
How has Avicanna performed financially in Q3 2025?
The company reported a revenue of $6.40 million for Q3 2025, showing growth in both Canadian and international markets.
What recent patents has Avicanna received?
Avicanna received a patent covering topical cannabinoid compositions aimed at treating skin conditions, demonstrating its commitment to innovation.
What international markets is Avicanna entering?
Avicanna recently completed the export of cannabis products to Switzerland, marking its entry into the European market.
How does Avicanna support patients?
The MyMedi.ca platform provides resources and support for medical cannabis patients, enhancing their overall experience and care.
